Merck, Ra Pharma enter drug-development deal worth up to $200M

04/2/2013 | Pharmaceutical Business Review Online · Xconomy

Merck and Ra Pharmaceuticals agreed to collaborate in the development of Cyclomimetics drug candidates against multiple therapeutic areas using the latter's Extreme Diversity platform. Cyclomimetics are peptidelike molecules that have the diversity and specificity of antibodies. The deal entitles Ra to about $200 million in payments including upfront fee, research funding and milestone fees.

View Full Article in:

Pharmaceutical Business Review Online · Xconomy

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC